sodium (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoate

• ChemBase ID: 169307
• Molecular Formular: C24H25FNNaO4
• Molecular Mass: 433.4477732
• Monoisotopic Mass: 433.16653079
• SMILES: c1cccc2c1c(c(n2C(C)C)/C=C/[C@H](C[C@H](CC(=O)[O-])O)O)c1ccc(cc1)F.[Na+]
• Canonical SMILES: [O-]C(=O)C[C@@H](C[C@@H](/C=C/c1c(c2ccc(cc2)F)c2c(n1C(C)C)cccc2)O)O.[Na+]
• InChI: InChI=1S/C24H26FNO4.Na/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30;/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30);/q;+1/p-1/b12-11+;/t18-,19-;/m1./s1
• InChIKey: ZGGHKIMDNBDHJB-NRFPMOEYSA-M

NAMES AND DATABASE IDS

Names

• IUPAC name: sodium (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoate
• IUPAC Traditional name: sodium (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropylindol-2-yl]-3,5-dihydroxyhept-6-enoate
• Synonyms: (3R,5S)-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic Acid Sodium Salt; (3R,5S)-Fluvastatin Sodium Salt; (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic Acid Sodium Salt; Fluindostatin; XU 62-320; Lescol; Lipaxan; Primexin; Fluvastatin Sodium Salt

Database IDs

• CAS Number: 94061-80-0; 93957-55-2
• PubChem SID: 162263439
• PubChem CID: 23663976

CALCULATED PROPERTIES

• Acid pKa: 4.55701
• H Acceptors: 4
• H Donor: 2
• LogD (pH = 5.5): 2.837187
• LogD (pH = 7.4): 1.0636245
• Log P: 3.8259492
• Molar Refractivity: 125.6924 cm^3
• Polarizability: 45.93319 Å^3
• Polar Surface Area: 85.52 Å^2
• Rotatable Bonds: 8
• Lipinski's Rule of Five: true

PROPERTIES

Physical Property

• Solubility: DMSO; Methanol; Water
• Apperance: Pale Yellow Solid
• Melting Point: >137°C (dec.); >150°C (dec.)

Safety Information

• Storage Condition: -20°C Freezer; -20°C Freezer, Under inert atmosphere

DETAILS

Toronto Research Chemicals - F601250

A synthetic HMG-CoA reductase inhibitor. Antilipemic.

Toronto Research Chemicals - F601245

A synthetic HMG-CoA reductase inhibitor. Antilipemic.This compound contains residual sodium chloride which is quantified on the certificate of analysis.

REFERENCES

• Yuan, J., et al.: Atherosclerosis, 87, 147 (1991)
• Tse, F.L.S., et al.: J. Clin. Pharmacol., 32, 630 (1991)
• Dain, J.G., et al.: Drug Metab. Disposit., 21, 567 (1991)
• Yuan, J., et al.: Atherosclerosis, 87, 147 (1991)
• Tse, F.L.S., et al.: J. Clin. Pharmacol., 32, 630 (1991)
• Dain, J.G., et al.: Drug Metab. Disposit., 21, 567 (1991)